Atogepant received FDA approval for the preventive treatment of episodic migraine in adults [1]. The approval was announced on September 27, 2021 [2].
When can the drug be used for migraine treatment?
Atogepant is indicated for adults who have experienced at least four migraine days per month during the previous three months [1].
What is Atogepant and how does it work?
Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pathophysiology. By blocking the CGRP receptor, atogepant is thought to interrupt the cascade of events leading to migraine attacks [3].
What other treatments are available for migraine?
Migraine treatment options include acute treatments taken at the onset of a migraine and preventive treatments used to reduce the frequency and severity of attacks [4]. Preventive options can include oral medications, injections, and newer CGRP pathway inhibitors [4]. Atogepant is one of the oral CGRP antagonists available for prevention [1][3].
Who makes Atogepant?
Atogepant is marketed by AbbVie [2].
What are the potential side effects of Atogepant?
Common side effects reported in clinical trials include upper respiratory tract infection, nausea, and fatigue [1].
What is the patent status for Atogepant?
Information regarding the patent exclusivity for atogepant can be found on DrugPatentWatch.com [5].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215198s000lbl.pdf
[2] https://www.prnewswire.com/news-releases/abbvie-announces-fda-approval-of-qulipta-atogepant-for-the-preventive-treatment-of-episodic-migraine-301385482.html
[3] https://pubmed.ncbi.nlm.nih.gov/33836436/
[4] https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204
[5] https://drugpatentwatch.com/